Utilizing biorecognition to prime tumors for enhanced nanomedicine delivery of alpha therapies

Journal of Controlled Release 2026 Open access

Read full text
Authors: Nicholas L. Fletcher, Weijing Chu, Pie Huda, Amber Prior, S. Gayathri, James Humphries, Christopher Howard, James L. Wood, Xiaoyan Zhang, Marina Silveira E. Silva, Benedict Lum, Malcolm Lim
+2 more Fiona Simpson, Kristofer J. Thurecht
DOI: 10.1016/j.jconrel.2026.114708
Cited by: 3
References: 55

Abstract

Pb-nanomedicine, with no observed long term hematological effects. This work establishes a modular strategy for targeted TRT nanomedicine delivery. The platform has potential for broad applicability, including simultaneous delivery of diverse or synergistic payloads. These findings represent an important advance toward precision nanomedicine approaches in radionuclide therapy.

Fields of Study & Subjects

Radiopharmaceutical Chemistry and Applications Radiation Therapy and Dosimetry Nanoplatforms for cancer theranostics

Publication details

Journal / source
Journal of Controlled Release
Publisher
Elsevier BV
Volume
392
Pages
114708–114708
Publication date
11 February 2026
Language
EN